CEBPB and metabolic dysfunction-associated steatohepatitis: In a diet-induced non-alcoholic steatohepatitis (NASH) model, treatment with 1-PPA, a recently identified Par2 inhibitor, effectively suppressed the PAR2—C/EBP-β—SerpinB3 axis, resulting in protection against NASH development and progression [76].